Vktx nasdaq.
Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...
Viking Therapeutics Stock Price, News & Analysis (NASDAQ:VKTX) $13.01 +0.79 (+6.46%) (As of 12/1/2023 ET) Today's Range $11.82 $13.10 50-Day Range $9.24 …XBI, TGTX, VKTX, NVAX: Large Outflows Detected at ETF. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P ...Feb 9, 2023 · Average portfolio weight of all funds dedicated to VKTX is 0.02%, a decrease of 20.95%. Total shares owned by institutions decreased in the last three months by 1.25% to 27,896K shares. The latest price target for . Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023.The analyst firm set a price target for 32.00 expecting VKTX to rise ...
Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes.
Viking Therapeutics (NASDAQ: VKTX) is one of the more exciting biopharma stocks out there. The firm is developing novel therapies to address endocrine and metabolic disorders. It has more than ...Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of
During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $ ...VKTX Viking Therapeutics Inc Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021Jun 27, 2023 · Looking at the chart above, VKTX's low point in its 52 week range is $2.5345 per share, with $25.7199 as the 52 week high point — that compares with a last trade of $15.54. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VKTX shares currently have a short interest ratio of 9.0. Learn More on Viking Therapeutics's short interest ratio.
Back to VKTX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.
According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00.
VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ...Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports.Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered …The Nasdaq Composite ... (VKTX 6.23%), whose shares jumped 48%. Viking is looking at a NASH treatment that could use an approach similar to that of Madrigal's candidate, and while Viking's drug is ...Impinj (PI) and Ambarella (AMBA) stocks are trading lower, while Viking Therapeutics (VKTX) is soaring after its public offeringVIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 72% based on the firm’s underlying fundamentals and the stock ...Standing squarely in the bull camp, BTIG analyst Justin Zelin rates VKTX a Buy along with a $20 price target. This target puts the upside potential at a whopping 221%. This target puts the upside ...Price Volume Sep '23 Oct '23 Nov '23 Dec '23 $10 $8 $12 $14 $16 $18 0M 10M 20M 2020. Display Events. Dividends. Splits. Earnings. News. Chart Style. Line. Mountain.
Viking Therapeutics Inc stock price (VKTX) NASDAQ: VKTX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Viking Therapeutics Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock.Dec 1, 2023 · 9 brokers have issued 1 year target prices for Viking Therapeutics' shares. Their VKTX share price targets range from $19.00 to $37.00. On average, they predict the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price. The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023. The analyst firm set a price target ...3,698,369. 784,592. 4.713748. Back to VKTX Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 minutes delayed.The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...
Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.
See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.A high-level overview of Viking Therapeutics, Inc. (VKTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Find the latest SEC Filings data for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Dec 4, 2023 · Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the […] Fintel reports that on May 3, 2023, Roth MKM maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 31.63% Upside. As of April 24 ...Weight-loss medicines are rising in popularity. According to some estimates, this market will be worth $44 billion in risk-adjusted sales by 2030, while it was only valued at $2.5 billion last ...Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ...In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $35.00.The company’s shares opened ...
Jun 29, 2023 · Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of $1.05. If an investor was to purchase shares of VKTX stock at the current price ...
About Viking Therapeutics Stock (NASDAQ:VKTX) Founded in 2012, Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on developing novel therapies for metabolic and endocrine disorders, including non-alcoholic steatohepatitis (NASH), hip fracture recovery, and type 2 diabetes.
Viking Therapeutics (NASDAQ: VKTX) is one of the more exciting biopharma stocks out there. The firm is developing novel therapies to address endocrine and metabolic disorders. It has more than ...Today's Change. (1.85%) $0.21. Current Price. $11.56. Price as of November 22, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.VKTX: Viking Therapeutics broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research. ... NASDAQ data is at least 15 minutes delayed.Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a ...Finally, the Nasdaq Composite is experiencing the worst drop today with a 0.39% decrease this morning. ... Why Is Viking Therapeutics (VKTX) Stock Moving Today? On the date of publication, ...May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease.Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.About Viking Therapeutics Stock (NASDAQ:VKTX) Founded in 2012, Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on developing novel therapies for metabolic and endocrine disorders, including non-alcoholic steatohepatitis (NASH), hip fracture recovery, and type 2 diabetes.Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
Viking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell My Personal ... Latest SEC filings for Viking Therapeutics, Inc. (VKTX).Instagram:https://instagram. sep ira providershow much is a 1979 one dollar coin worthcompanies like lockheed martinshort stocks list Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of various metabolic disorders. auto trade botstocks under 5 dollars a share Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,829 shares of the biotechnology company’s stock, valued at approximately $2,072,000. Rhumbline …Principal Financial Group Inc. bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to the company in its most recent Form 13F filing ... beyond burgers costco Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Viking Therapeutics last announced its quarterly earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per share).